Author Archives: Joana Carvalho

The nonprofit teaching hospital Holy Cross Health has partnered with the COPD Foundation to open a pilot program to help people with chronic obstructive pulmonary disease (COPD) and related lung disorders in managing their health at their homes. Funded by Herb Yardley, a member of the foundation’s board…

A new Alexa healthcare skill, called the Emmi Care Plan, provides a voice service that allows patients to easily remain in contact with their healthcare providers while recovering at home after being discharged from the hospital. It’s being launched by Wolters Kluwer, Health, a global leader in providing…

Older patients with chronic obstructive pulmonary disease (COPD) taking oral, synthetically-made cannabinoids — medications based on compounds found naturally in marijuana (the plant Cannabis sativa) — to manage some of their symptoms have a 64% higher risk of death compared to those not taking the medications, according to…

Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — called ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) — are each expected to enroll up to 800 patients…

Chronic obstructive pulmonary disease (COPD) is more prevalent than previously thought and associated with a mortality rate that is likely higher than earlier estimates, a review study has found. Invasive aspergillosis — a respiratory infection caused by molds belonging to the Aspergillus genus — may be a…

PR1P, a small peptide able to increase the activity of vascular endothelial growth factor (VEGF) in cells lining the inside of blood vessels, can reduce lung cell death and tissue damage in a mouse model of emphysema, a study reports. According to investigators, these findings highlight the therapeutic…

Breztri Aerosphere, AstraZeneca’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of the disease, a Phase 3 trial shows. The findings were presented…

Remestemcel-L, Mesoblast’s lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease (COPD) and a high degree of inflammation, data from a post-hoc analysis of a Phase 2 trial show. Findings were presented in an…

Chronic obstructive pulmonary disease (COPD) is linked to a higher risk of lung cancer in people who never smoked. In fact, their risk is equivalent to current or former smokers who do not have COPD, a research team reports. The study, “Chronic obstructive pulmonary disease…

Duaklir (aclidinium bromide and formoterol fumarate), a long-term maintenance treatment for chronic obstructive pulmonary disease (COPD), is  available to patients living in the U.S., Circassia Pharmaceuticals announced. According to the company, the product became available on Oct. 21. The U.S. Food and Drug Administration…